STUDY OBJECTIVES: To describe patterns of prescribing augmentation therapy, and types and rates of adverse events in the National Heart, Lung, and Blood Institute Registry for Individuals with Severe Deficiency of Alpha(1)-Antitrypsin. DESIGN: Observational cohort study with follow-up visits every 6 to 12 months for up to 7 years. MEASUREMENTS: The rate and dosing frequency with which Registry participants were prescribed to receive augmentation therapy by their managing physicians, and the type and frequency of adverse events, classified in two ways: severity of self-reported symptoms, and actions taken as a consequence of the symptom. RESULTS: Over the course of Registry follow-up, 66% (n = 747) of the participants received augmentation therapy at some time. In keeping with recommendations made in the 1989 American Thoracic Society (ATS) statement, 75% of participants with airflow obstruction at first visit (defined as FEV(1) < 80% predicted) received augmentation therapy within 3 years, though some participants with FEV(1) > or = 80% predicted (14%) also received augmentation therapy. Among those with COPD for whom augmentation therapy was not prescribed, financial constraints were the reported cause in 30%. Observed patterns also varied from approved practice, in that dosing frequencies other than the US Food and Drug Administration-approved, once-weekly regimen were frequently prescribed. The overall rate of reported adverse events was 0.02 per patient-month, with 83% of participants reporting no events. This overall rate was composed of 16% considered mild events, 76% moderate events, and 9% severe events. CONCLUSIONS: We conclude that augmentation therapy was generally well tolerated and, consistent with ATS guidelines, physicians generally did not prescribe augmentation therapy for subjects with FEV(1) > or = 80% predicted. However, the large percentage of subjects with FEV(1) <80% predicted not receiving augmentation therapy and the frequent use of 2- to 3-week or monthly dosing reflects variation of practice from suggested treatment guidelines.
STUDY OBJECTIVES: To describe patterns of prescribing augmentation therapy, and types and rates of adverse events in the National Heart, Lung, and Blood Institute Registry for Individuals with Severe Deficiency of Alpha(1)-Antitrypsin. DESIGN: Observational cohort study with follow-up visits every 6 to 12 months for up to 7 years. MEASUREMENTS: The rate and dosing frequency with which Registry participants were prescribed to receive augmentation therapy by their managing physicians, and the type and frequency of adverse events, classified in two ways: severity of self-reported symptoms, and actions taken as a consequence of the symptom. RESULTS: Over the course of Registry follow-up, 66% (n = 747) of the participants received augmentation therapy at some time. In keeping with recommendations made in the 1989 American Thoracic Society (ATS) statement, 75% of participants with airflow obstruction at first visit (defined as FEV(1) < 80% predicted) received augmentation therapy within 3 years, though some participants with FEV(1) > or = 80% predicted (14%) also received augmentation therapy. Among those with COPD for whom augmentation therapy was not prescribed, financial constraints were the reported cause in 30%. Observed patterns also varied from approved practice, in that dosing frequencies other than the US Food and Drug Administration-approved, once-weekly regimen were frequently prescribed. The overall rate of reported adverse events was 0.02 per patient-month, with 83% of participants reporting no events. This overall rate was composed of 16% considered mild events, 76% moderate events, and 9% severe events. CONCLUSIONS: We conclude that augmentation therapy was generally well tolerated and, consistent with ATS guidelines, physicians generally did not prescribe augmentation therapy for subjects with FEV(1) > or = 80% predicted. However, the large percentage of subjects with FEV(1) <80% predicted not receiving augmentation therapy and the frequent use of 2- to 3-week or monthly dosing reflects variation of practice from suggested treatment guidelines.
Authors: Darcy D Marciniuk; P Hernandez; M Balter; J Bourbeau; K R Chapman; G T Ford; J L Lauzon; F Maltais; D E O'Donnell; D Goodridge; C Strange; A J Cave; K Curren; S Muthuri Journal: Can Respir J Date: 2012 Mar-Apr Impact factor: 2.409
Authors: William J Savage; Aaron A R Tobian; Jessica H Savage; Robert A Wood; John T Schroeder; Paul M Ness Journal: Transfusion Date: 2012-09-24 Impact factor: 3.157
Authors: P Marco Fisichella; Christopher S Davis; Erin Lowery; Luis Ramirez; Richard L Gamelli; Elizabeth J Kovacs Journal: J Am Coll Surg Date: 2013-04-28 Impact factor: 6.113
Authors: A Mario Marcondes; Xiang Li; Laura Tabellini; Matthias Bartenstein; Julia Kabacka; George E Sale; John A Hansen; Charles A Dinarello; H Joachim Deeg Journal: Blood Date: 2011-09-06 Impact factor: 22.113
Authors: Eli C Lewis; Mark Mizrahi; Michel Toledano; Nathaniel Defelice; Joanne L Wright; Andrew Churg; Leland Shapiro; Charles A Dinarello Journal: Proc Natl Acad Sci U S A Date: 2008-10-13 Impact factor: 11.205
Authors: Amit Gaggar; Junliang Chen; James F Chmiel; Henry L Dorkin; Patrick A Flume; Rhonda Griffin; David Nichols; Scott H Donaldson Journal: J Cyst Fibros Date: 2015-08-28 Impact factor: 5.482